BioLineRx Ltd. (NASDAQ:BLRX) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Wednesday.

According to Zacks, “Bioline RX Ltd. is a biopharmaceutical development company. BioLineRx is dedicated to building a portfolio of products for unmet medical needs or with advantages over currently available therapies. The Company’s portfolio consists of clinical stage candidates including BL-1020 for schizophrenia , BL-1040, for treatment of patients following a myocardial infarction, BL-5010 for non-surgical removal of skin lesions, BL-1021 for neuropathic pain and BL-7040 for treating Inflammatory Bowel Disease. In addition, BioLineRx has many products in various pre-clinical development stages for a variety of indications, including central nervous system diseases, oncology, infectious diseases, cardiovascular and autoimmune diseases. “

Several other brokerages have also recently commented on BLRX. HC Wainwright set a $4.00 price target on shares of BioLineRx and gave the stock a “buy” rating in a research report on Tuesday, April 18th. Maxim Group set a $3.00 price target on shares of BioLineRx and gave the stock a “buy” rating in a research report on Thursday, May 25th. Finally, ValuEngine raised shares of BioLineRx from a “sell” rating to a “hold” rating in a research report on Monday, July 17th. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $3.18.

BioLineRx (NASDAQ:BLRX) traded up 3.7189% during trading on Wednesday, reaching $0.9594. The company’s stock had a trading volume of 758,930 shares. The company’s 50 day moving average price is $0.87 and its 200 day moving average price is $0.96. BioLineRx has a 52 week low of $0.75 and a 52 week high of $1.42. The company’s market cap is $59.27 million.

BioLineRx (NASDAQ:BLRX) last announced its earnings results on Thursday, May 25th. The biotechnology company reported ($0.08) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.05) by $0.03. On average, equities analysts anticipate that BioLineRx will post ($0.24) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “BioLineRx Ltd. (BLRX) Upgraded to “Hold” at Zacks Investment Research” was originally reported by American Banking News and is owned by of American Banking News. If you are accessing this report on another publication, it was copied illegally and republished in violation of United States and international copyright and trademark legislation. The original version of this report can be read at https://www.americanbankingnews.com/2017/07/26/biolinerx-ltd-blrx-upgraded-to-hold-at-zacks-investment-research.html.

Several large investors have recently modified their holdings of BLRX. Sabby Management LLC bought a new stake in BioLineRx during the first quarter worth about $3,018,000. KCG Holdings Inc. raised its stake in shares of BioLineRx by 715.9% in the first quarter. KCG Holdings Inc. now owns 175,156 shares of the biotechnology company’s stock valued at $168,000 after buying an additional 153,687 shares during the period. Renaissance Technologies LLC acquired a new stake in shares of BioLineRx during the first quarter valued at $126,000. Benchmark Capital Advisors raised its stake in shares of BioLineRx by 227.3% in the first quarter. Benchmark Capital Advisors now owns 144,000 shares of the biotechnology company’s stock valued at $138,000 after buying an additional 100,000 shares during the period. Finally, Citadel Advisors LLC raised its stake in shares of BioLineRx by 443.4% in the first quarter. Citadel Advisors LLC now owns 105,986 shares of the biotechnology company’s stock valued at $102,000 after buying an additional 86,481 shares during the period. 38.00% of the stock is currently owned by institutional investors.

BioLineRx Company Profile

BioLine RX Ltd is an Israel-based company engaged in the development of therapeutics, from preclinical-stage development to advanced clinical trials, for a range of medical needs. Its clinical therapeutic candidates under development consist of BL-1020 that is in Phase II/III clinical trials to improve cognitive function in schizophrenia patients; BL-1040, which is under pivotal CE-Mark registration trial for the prevention of cardiac remodeling following an acute myocardial infarction; BL-5010, which has completed Phase I/II clinical trials for non-surgical removal of skin lesions; BL-1021 that has completed Phase Ia clinical trial for the treatment of neuropathic pain or pain that results from damage to nerve fibers, and BL-7040, a synthetic oligonucleotide, which is in Phase II clinical trial for the treatment of inflammatory bowel disease.

Get a free copy of the Zacks research report on BioLineRx (BLRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for BioLineRx Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLineRx Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.